查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930134

全球C反应蛋白检测市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

C-Reactive Protein Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 请询问到货日

价格

C反应蛋白（CRP）检测市场的成长驱动因子

由于慢性病盛行率的上升、即时检测（POC）的广泛应用以及人们对CRP作为发炎标记物作用的认识不断提高，全球C反应蛋白（CRP）检测市场预计将稳步成长。根据Fortune Business Insights预测，该市场规模在2025年达到25.5亿美元，预计2026年成长至26.9亿美元，到2034年达到39.5亿美元，预测期内年复合成长率（CAGR）为4.9%。到2025年，北美以 34.5%的市场占有率引领市场，这主要得益于高疾病负担、先进的医疗基础设施以及对 CRP 即时检测日益成长的需求。

CRP 是一种非特异性发炎标记物，在预测心血管风险（包括心臟病发作和中风）方面发挥重要作用。它也用于诊断癌症、类风湿性关节炎和其他自体免疫疾病等慢性疾病。 CRP 检测设备和试剂盒（包括即时检测解决方案）的技术进步进一步推动市场成长。

市场动态

驱动因素

心血管疾病、癌症和自体免疫疾病等慢性疾病的日益普遍推动对 CRP 检测的需求。根据美国疾病管制与预防中心（CDC）2022年的资料，美国约有 2,010万成年人患有冠状动脉疾病，每年约有 80.5万例心肌梗塞。患者群体不断扩大以及对预防保健的日益重视，正推动着 CRP 检测在全球的普及。

另一个主要驱动因素是即时检测（POC）CRP 检测的发展，这有助于临床医生减少抗生素处方并提高诊断效率。例如，发表在《英国全科医学杂誌》（2022）上的一项研究强调了使用 CRP POC 检测来诊断急性呼吸道感染，最大限度地减少不必要的抗生素使用。 Bloom Diagnostics 和 LumiraDx 等公司已推出先进的POC CRP 检测，以满足这一日益成长的需求。

趋势

市场对技术先进的检测试剂盒和设备越来越感兴趣。免疫比浊法检测在2026年将占据市场主导地位，市场占有率高达75.09%，主要得益于产品的广泛应用和临床实验室的广泛采用。高敏感性C反应蛋白（hs-CRP）检测在心血管风险评估中日益受到关注。此外，社区医疗机构中即时检测（POC）的日益普及预计将进一步推动市场成长。

限制因子

CRP是一种非特异性发炎标记物，因此其作为独立诊断检测的应用受到限制。冠状动脉CT血管摄影、心电图（ECG）和运动负荷试验等替代诊断方法能够提供更准确、更具疾病特异性的结果。这些替代方法的出现可能会在一定程度上减缓CRP检测的普及。

市场区隔

依产品分类：市场分为试剂和试剂盒以及设备。试剂和试剂盒市场主要受检测量大和Abbott、LumiraDx等大型公司强大的产品阵容推动，预计到2026年将占据73.61%的市场占有率。由于创新型设备（例如2022年获得美国FDA批准的ProciseDx设备）的监管批准不断增加，预计设备市场也将成长。

依检测类型划分：市场分为免疫比浊法、酵素连结免疫吸附试验（ELISA）、化学发光免疫分析法（CLIA）及其他方法。免疫比浊法因其易用性和广泛应用而占据市场主导地位，而ELISA和CLIA检测方法也呈现稳定成长，尤其是在慢性病检测方面。

依检测范围划分：到2026年，传统C反应蛋白（CRP）检测将占据89.96%的市场占有率，主要用于监测慢性病和自体免疫疾病。高敏C反应蛋白检测日益用于心血管风险评估。

依检测方式划分：实验室检测凭藉其先进且全面的分析能力，将在2026年占据75.84%的市场占有率，保持领先地位。同时，即时检测（POC）预计将在资源匮乏地区和基层医疗机构实现显着成长。

依最终用户划分：由于慢性病管理检测数量的增加，诊断实验室将引领市场。同时，由于住院人数和临床需求的增加，医院和诊所预计将强劲成长。

区域洞察

  • 北美：8.8亿美元（2025年），8.5亿美元（2026年）。美国市场的成长动力来自慢性病负担、创新和临床研究。
  • 欧洲：英国：1.02亿美元，德国：1.08亿美元（2026年）。监管审批、CE认证产品以及自体免疫疾病监测领域日益成长的应用将推动市场成长。
  • 亚太地区：日本：1.5亿美元，中国：2.2亿美元，印度：1.1亿美元（2026年）。主要驱动因素包括慢性病流行、公共卫生措施以及策略伙伴关係，例如FIND-SD生物感测器合作计画。
  • 拉丁美洲、中东和非洲：由于医疗基础设施的改善和快速诊断测试的广泛应用，预计将实现温和成长。

主要行业参与者

该市场的主要公司包括Abbott、F. Hoffmann-La Roche Ltd.、Siemens Healthcare、Quest Diagnostics、Thermo Fisher Scientific、Merck KGaA、Getein Biotech、Randox Laboratories、Boditech Med、LumiraDx。市场参与者专注于研发、新产品发布以及拓展即时检测（POC）产品线。例如，Abbott于2016年收购了Alere Inc.，扩展了其即时检测产品组合。

值得注意的进展包括：Siemens的CardioPhase hs-CRP 检测获得 FDA 批准（2022年 12月），以及与 Boditech Med 就其进入北美市场签署谅解备忘录（2022年 3月）。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家和地区主要慢性病盛行率
  • C反应蛋白检测技术进展
  • 新产品发布
  • 关键产业趋势：併购、业务合作等
  • 新冠疫情对市场的影响

第5章 全球市场C反应蛋白检测市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 试剂和试剂盒
    • 仪器
  • 市场分析、洞察与预测：依检测类型分类
    • 化学发光免疫分析法（CLIA）
    • 酵素连结免疫吸附试验（ELISA）
    • 免疫比浊法
    • 其他
  • 市场分析、洞察与预测：依检测范围分类
    • 常规CRP
    • 高敏感性CRP
  • 市场分析、洞察与预测：依操作环境分类
    • 实验室检测
    • 即时侦测（POC）侦测
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 诊断实验室
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美 C 反应蛋白检测市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲 C 反应蛋白检测市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家

第8章 亚太地区 C 反应蛋白检测市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区

第9章 拉丁美洲 C 反应蛋白检测市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲 C 反应蛋白检测市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Getein Biotech, Inc.
  • Randox Laboratories Ltd.
  • BODITECH MED, INC.
  • LumiraDx
Product Code: FBI107164

Growth Factors of C-reactive protein (CRP) testing Market

The global C-reactive protein (CRP) testing market is projected to witness steady growth due to the rising prevalence of chronic diseases, increasing adoption of point-of-care (POC) testing, and growing awareness about the role of CRP as an inflammation marker. According to Fortune Business Insights, the market was valued at USD 2.55 billion in 2025, expected to grow to USD 2.69 billion in 2026, and is forecasted to reach USD 3.95 billion by 2034, registering a CAGR of 4.9% during the forecast period. North America dominated the market in 2025 with a share of 34.5%, driven by high disease burden, advanced healthcare infrastructure, and growing preference for CRP point-of-care tests.

CRP is a non-specific marker of inflammation and plays a critical role in predicting cardiovascular risks, including heart attack and stroke. It is also used in diagnosing chronic conditions such as cancer, rheumatoid arthritis, and other autoimmune diseases. The market growth is further supported by technological advancements in CRP testing instruments and kits, including POC solutions.

Market Dynamics

Drivers

The increasing prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders, has driven the demand for CRP testing. According to CDC data from 2022, approximately 20.1 million adults in the U.S. suffer from coronary artery disease, with an estimated 805,000 heart attacks occurring annually. The rising patient population and growing focus on preventive healthcare have fueled the adoption of CRP testing globally.

Another major driver is the development of point-of-care CRP tests, which aid clinicians in reducing antibiotic prescriptions and improving diagnostic efficiency. For instance, research published in the British Journal of General Practice (2022) highlighted the use of CRP POC testing for acute respiratory infections to minimize unnecessary antibiotic use. Companies such as Bloom Diagnostics and LumiraDx are launching advanced POC CRP tests to address this growing need.

Trends

The market is witnessing a growing focus on technologically advanced testing kits and instruments. The immunoturbidimetric assay segment dominated the market in 2026 with a 75.09% share, due to widespread product availability and strong adoption in clinical laboratories. High-sensitivity CRP (hs-CRP) testing is gaining traction for cardiovascular risk assessment. Additionally, the increasing use of POC tests in community healthcare settings is expected to drive growth further.

Restraints

CRP is a non-specific inflammation marker, which limits its use as a standalone diagnostic test. Alternative diagnostics, such as coronary CT angiography, electrocardiography (ECG), and stress tests, provide more accurate disease-specific results. The availability of these alternatives may slow the adoption of CRP tests to some extent.

Market Segmentation

By Product: The market is divided into reagents & kits and instruments. Reagents & kits dominated with a 73.61% share in 2026, driven by high testing volumes and strong offerings from key players like Abbott and LumiraDx. The instruments segment is expected to grow due to increasing regulatory approvals for innovative devices, such as the ProciseDx instrument approved by the U.S. FDA in 2022.

By Assay Type: The market is segmented into immunoturbidimetric assay, ELISA, CLIA, and others. Immunoturbidimetric assays lead due to ease of use and widespread adoption, while ELISA and CLIA-based assays are steadily growing, particularly for chronic disease detection.

By Detection Range: Conventional CRP dominated with an 89.96% share in 2026, primarily for chronic and autoimmune disease monitoring. High-sensitivity CRP tests are increasingly used for cardiovascular risk assessment.

By Setting: Laboratory testing led with 75.84% share in 2026, attributed to precise and comprehensive analysis. POC testing is expected to grow significantly in resource-limited or primary care settings.

By End-User: Diagnostic laboratories dominate due to the increasing number of tests for chronic disease management, while hospitals and clinics are expected to witness strong growth due to rising hospitalizations and clinical demand.

Regional Insights

  • North America: USD 0.88B (2025), USD 0.85B (2026); dominated by U.S. chronic disease burden, innovation, and clinical research.
  • Europe: UK USD 0.12B, Germany USD 0.18B (2026); growth supported by regulatory approvals, CE-marked products, and rising adoption for autoimmune disease monitoring.
  • Asia Pacific: Japan USD 0.15B, China USD 0.22B, India USD 0.11B (2026); driven by chronic disease prevalence, public health initiatives, and strategic partnerships such as FIND-SD Biosensor collaborations.
  • Latin America & Middle East/Africa: Moderate growth due to improving healthcare infrastructure and adoption of rapid diagnostic tests.

Key Industry Players

Prominent companies in the market include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Merck KGaA, Getein Biotech, Randox Laboratories, Boditech Med, and LumiraDx. Market players are focusing on research and development, new product launches, and expanding POC offerings. For instance, Abbott's acquisition of Alere Inc. in 2016 expanded its POC testing portfolio.

Notable developments include Siemens FDA clearance for CardioPhase hs-CRP test (Dec 2022) and Boditech Med MoU for North American market entry (Mar 2022).

Conclusion

The global C-reactive protein testing market is projected to grow from USD 2.55 billion in 2025 to USD 3.95 billion by 2034, supported by rising chronic disease prevalence, increasing adoption of POC tests, and continuous innovation in assay technologies. Despite limitations due to alternative diagnostics, CRP testing remains a vital tool for inflammation monitoring, cardiovascular risk prediction, and improving patient management worldwide.

Segmentation By Product, Assay Type, Detection Range, Setting, End User, and Region

By Product * Reagents & Kits

  • Instruments

By Assay Type * Chemiluminescence Immunoassay (CLIA)

  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunoturbidimetric Assay
  • Others

By Detection Range * Conventional CRP

  • hs-CRP

By Setting

Laboratory Testing

  • Point-of-Care (POC) Testing

By End User * Hospitals & Clinics

  • Diagnostic Laboratories
  • Others

By Region * North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)

    • U.S.
    • Canada
  • Europe (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions
  • 4.2. Technological Advancements in C-Reactive Protein Testing
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Reagents & Kits
    • 5.1.2. Instruments
  • 5.2. Market Analysis, Insights and Forecast - By Assay Type
    • 5.2.1. Chemiluminescence Immunoassay (CLIA)
    • 5.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.2.3. Immunoturbidimetric Assay
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Detection Range
    • 5.3.1. Conventional CRP
    • 5.3.2. Hs-CRP
  • 5.4. Market Analysis, Insights and Forecast - By Setting
    • 5.4.1. Laboratory Testing
    • 5.4.2. Point-of-Care (POC) Testing
  • 5.5. Market Analysis, Insights and Forecast - By End-User
    • 5.5.1. Hospitals & Clinics
    • 5.5.2. Diagnostic Laboratories
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Reagents & Kits
    • 6.1.2. Instruments
  • 6.2. Market Analysis, Insights and Forecast - By Assay Type
    • 6.2.1. Chemiluminescence Immunoassay (CLIA)
    • 6.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.2.3. Immunoturbidimetric Assay
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Detection Range
    • 6.3.1. Conventional CRP
    • 6.3.2. Hs-CRP
  • 6.4. Market Analysis, Insights and Forecast - By Setting
    • 6.4.1. Laboratory Testing
    • 6.4.2. Point-of-Care (POC) Testing
  • 6.5. Market Analysis, Insights and Forecast - By End-User
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Diagnostic Laboratories
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Reagents & Kits
    • 7.1.2. Instruments
  • 7.2. Market Analysis, Insights and Forecast - By Assay Type
    • 7.2.1. Chemiluminescence Immunoassay (CLIA)
    • 7.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 7.2.3. Immunoturbidimetric Assay
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Detection Range
    • 7.3.1. Conventional CRP
    • 7.3.2. Hs-CRP
  • 7.4. Market Analysis, Insights and Forecast - By Setting
    • 7.4.1. Laboratory Testing
    • 7.4.2. Point-of-Care (POC) Testing
  • 7.5. Market Analysis, Insights and Forecast - By End-User
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Diagnostic Laboratories
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Rest of Europe

8. Asia Pacific C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Reagents & Kits
    • 8.1.2. Instruments
  • 8.2. Market Analysis, Insights and Forecast - By Assay Type
    • 8.2.1. Chemiluminescence Immunoassay (CLIA)
    • 8.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 8.2.3. Immunoturbidimetric Assay
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Detection Range
    • 8.3.1. Conventional CRP
    • 8.3.2. Hs-CRP
  • 8.4. Market Analysis, Insights and Forecast - By Setting
    • 8.4.1. Laboratory Testing
    • 8.4.2. Point-of-Care (POC) Testing
  • 8.5. Market Analysis, Insights and Forecast - By End-User
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Diagnostic Laboratories
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. Australia
    • 8.6.5. Rest of Asia Pacific

9. Latin America C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Reagents & Kits
    • 9.1.2. Instruments
  • 9.2. Market Analysis, Insights and Forecast - By Assay Type
    • 9.2.1. Chemiluminescence Immunoassay (CLIA)
    • 9.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 9.2.3. Immunoturbidimetric Assay
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Detection Range
    • 9.3.1. Conventional CRP
    • 9.3.2. Hs-CRP
  • 9.4. Market Analysis, Insights and Forecast - By Setting
    • 9.4.1. Laboratory Testing
    • 9.4.2. Point-of-Care (POC) Testing
  • 9.5. Market Analysis, Insights and Forecast - By End-User
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Diagnostic Laboratories
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Reagents & Kits
    • 10.1.2. Instruments
  • 10.2. Market Analysis, Insights and Forecast - By Assay Type
    • 10.2.1. Chemiluminescence Immunoassay (CLIA)
    • 10.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 10.2.3. Immunoturbidimetric Assay
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Detection Range
    • 10.3.1. Conventional CRP
    • 10.3.2. Hs-CRP
  • 10.4. Market Analysis, Insights and Forecast - By Setting
    • 10.4.1. Laboratory Testing
    • 10.4.2. Point-of-Care (POC) Testing
  • 10.5. Market Analysis, Insights and Forecast - By End-User
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Diagnostic Laboratories
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 11.2.1. Abbott
      • 11.2.1.1. Overview,
      • 11.2.1.2. Product,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. F. Hoffmann-La Roche Ltd.
      • 11.2.2.1. Overview,
      • 11.2.2.2. Product,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Siemens Healthcare Private Limited
      • 11.2.3.1. Overview,
      • 11.2.3.2. Product,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Quest Diagnostics Incorporated
      • 11.2.4.1. Overview,
      • 11.2.4.2. Product,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Thermo Fisher Scientific, Inc.
      • 11.2.5.1. Overview,
      • 11.2.5.2. Product,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Merck KGaA
      • 11.2.6.1. Overview,
      • 11.2.6.2. Product,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Getein Biotech, Inc.
      • 11.2.7.1. Overview,
      • 11.2.7.2. Product,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Randox Laboratories Ltd.
      • 11.2.8.1. Overview,
      • 11.2.8.2. Product,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. BODITECH MED, INC.
      • 11.2.9.1. Overview,
      • 11.2.9.2. Product,
      • 11.2.9.3. SWOT Analysis,
      • 11.2.9.4. Recent Developments,
      • 11.2.9.5. Strategies,
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. LumiraDx
      • 11.2.10.1. Overview,
      • 11.2.10.2. Product,
      • 11.2.10.3. SWOT Analysis,
      • 11.2.10.4. Recent Developments,
      • 11.2.10.5. Strategies,
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 3: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 4: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 5: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 6: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 8: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 9: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 10: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 11: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 12: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 15: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 16: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 17: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 18: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 20: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 21: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 22: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 24: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 26: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 27: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 28: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 29: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 30: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 32: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 33: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 34: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 35: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 36: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global C-Reactive Protein Testing Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global C-Reactive Protein Testing Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025 & 2034
  • Figure 4: Global C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025 & 2034
  • Figure 5: Global C-Reactive Protein Testing Market Value Share (%), by Setting, 2025 & 2034
  • Figure 6: Global C-Reactive Protein Testing Market Value Share (%), by End-User, 2025 & 2034
  • Figure 7: Global C-Reactive Protein Testing Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 10: North America C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 11: North America C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 12: North America C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 13: North America C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 14: North America C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 15: North America C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 16: North America C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 17: North America C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 18: North America C-Reactive Protein Testing Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America C-Reactive Protein Testing Market Value Share (%), By Country, 2025
  • Figure 20: Europe C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 21: Europe C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 22: Europe C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 23: Europe C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 24: Europe C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 25: Europe C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 26: Europe C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 27: Europe C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 28: Europe C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 29: Europe C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 30: Europe C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 34: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 35: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 36: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 37: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 38: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 39: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 40: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 41: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 42: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 45: Latin America C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 46: Latin America C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 47: Latin America C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 48: Latin America C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 49: Latin America C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 50: Latin America C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 51: Latin America C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 52: Latin America C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 53: Latin America C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 54: Latin America C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 57: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 58: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 59: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 60: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 61: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 62: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 63: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 64: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 65: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 66: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global C-Reactive Protein Testing Market Share (%), By Company, 2025